Lenalidomide for Treatment of Myelodysplastic Syndromes

Title:Lenalidomide for Treatment of Myelodysplastic Syndromes

Volume: 18 Issue: 22

Author(s): Rami S. Komrokji and Alan F. List

Affiliation:

Keywords: Lenalidomide, myelodysplastic syndromes, deletion 5q, non-del(5q), immunomodulatory agent (IMiD), bone marrow failure, anemia, cytokines, apoptosis, myeloblast

Abstract: Lenalidomide is a second generation immunomodulatory agent (IMiD), which currently represents the standard of care for treatment of transfusion dependent lower risk myelodysplastic syndrome (MDS) patients with deletion (5q). Lenalidomide has unique activity with a high transfusion independence rate observed in this subset of patients. In this article we summarize the clinical experience using lenalidomide for treatment of del (5q) MDS. We highlight the mechanism of action and the recent advances in understanding the biology of del (5q) MDS. We also explore its potential use and the efforts to further improve its activity in non-del (5q) MDS.

Cite this article as:

S. Komrokji Rami and F. List Alan, Lenalidomide for Treatment of Myelodysplastic Syndromes, Current Pharmaceutical Design 2012; 18 (22) . https://dx.doi.org/10.2174/1381612811209023198